WuXi Bids Farewell To US Listing As It Vows To ‘Revolutionize R&D’
This article was originally published in PharmAsia News
Executive Summary
Being a private company affords WuXi to be more focused on chasing its new drug R&D dream, says the contract clinical research-focused group. But many see a relisting of the company before too long, this time on China's A-share market rather than in the US, in a pattern already established by several other Chinese firms.
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.
China Biotechs, CDMOs Embrace Uncertain Future, New Options Amid WuXi Woes
The shockwave of WuXi's withdrawal from BIO is ripping through the Chinese contract services sector. While some remain hopeful, others are preparing Plan B.